For instance, abatacept (ABT, which interrupts the costimulation molecule signal between T and B cells) [55], rituximab (RTX, which targets CD20+ B cells) [56], and tocilizumab (TCZ, which is an IL-6 receptor (IL-6R) antagonist) [57] have demonstrated high treatment efficacy in patients with active RA, particularly in those with inadequate responses to TNF-inhibitor treatment [58]. This evidence concerns the gene TNF and rheumatoid arthritis.